Nufarm – investment update

This week, Craig Shepherd does a deep dive into Nufarm after the FY-24 results were released last week. The results were good, and by yesterday the stock’s price had risen by 10%.
The market was especially cautious about the result given the company had downgraded its earnings expectations in August. But the result was at least as good as expected, and compositionally ahead of market expectations. The outlook the company provided, along with the details provided in the accompanying commentary, assurance for future profit growth.
In turn, in a related impact of this thematic, we have more recently added positions in pathology stocks (Healius and ACL) as well as a small position in the portfolio in NIB, one of Australia’s largest health insurers.
This week Craig Shepherd covers NIB a company that has a demonstrable track record of outperformance over the past 2 decades. The company has steadily grown policy holder numbers at a rate far exceeding that of the system.